The association of serum adiponectin levels with histopathological variables in gastric cancer patients

Medical Oncology

Volumn 27, Issue 4, 2010, Pages 1319-1323

  Seker, Mesut ^a   Bilici, Ahmet ^a   Sonmez, Berkant ^a   Ustaalioğlu, Bala Basak Oven ^a   Gumus, Mahmut ^a   Gozu, Hulya ^a   Sargin, Mehmet ^a   Orcun, Asuman ^a   Gezen, Cem ^a   Eser, Mehmet ^a   Bildik, Nejdet ^a   Salepci, Taflan ^a  

^a DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Gastric cancer; Histopathological variables; Serum adiponectin

Indexed keywords

ADIPONECTIN; C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; ENDOMETRIUM CANCER; FEMALE; GASTRECTOMY; HISTOPATHOLOGY; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LYMPH NODE DISSECTION; MALE; OBESITY; PRIORITY JOURNAL; STOMACH CANCER;

EID: 79951773868     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9382-x     Document Type: Article

References (24)

1. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348:1625-38. (Pubitemid 36459468)
2. Bergstrom A, Pisani P, Tenet V, et al. Overweight as an avoidable cause of cancer in Europe. Int J Cancer. 2001;91:421-30. (Pubitemid 32049639)
3. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med. 1999;130:883-90. (Pubitemid 29239582)
4. Vaughan TL, Farrow DC, Hansten PD, et al. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev. 1998;7:749-56. (Pubitemid 28420612)
5. Ishikawa M, Kitayama J, Kazama S, et al. Plasma adiponectin and gastric cancer. Clin Cancer Res. 2005;11:466-72. (Pubitemid 40116868)
6. Fraser-Moodie CA, Norton B, Gornall C, et al. Weight loss has an independent beneficial effect on symptoms of gastrooesophageal reflux in patients who are overweight. Scand J Gastroenterol. 1999;34:337-40. (Pubitemid 29232366)
7. Terry P, Lagergren J, Wolk A, et al. Reflux-inducing dietary factors and risk of adenocarcinoma of the esophagus and gastric cardia. Nutr Cancer. 2000;38:186-91. (Pubitemid 32762018)
8. Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab. 2004;30:13-9.
9. Maeda K, Okubo K, Shimomura I, et al. Analysis of an expression profile of genes in the human adipose tissue. Gene. 1997;190:227-35. (Pubitemid 27220127)
10. Stefan N, Stumvoll M. Adiponectin-its role in metabolism and beyond. Horm Metab Res. 2002;34:469-74.
11. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79-83. (Pubitemid 29299050)
12. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930-5. (Pubitemid 32472900)
13. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002;87:2764-9. (Pubitemid 34655342)
14. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595-9. (Pubitemid 30353893)
15. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002;360:57-8. (Pubitemid 34756495)
16. Vozarova B, Stefan N, Lindsay RS, et al. Low plasma adiponectin concentrations do not predict weight gain in humans. Diabetes. 2002;51:2964-7.
17. Dal Maso L, Augustin LS, Karalis A, et al. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab. 2004;89:1160-3. (Pubitemid 38368405)
18. Mantzoros C, Petridou E, Dessypris N, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004;89:1102-7. (Pubitemid 38368397)
19. Miyoshi Y, Funahashi T, Kihara S, et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res. 2003;9:5699-704. (Pubitemid 37499493)
20. Nakajima TE, Yamada Y, Hamano T. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol. 2009;44:685-90.
21. Petridou E, Mantzoros C, Dessypris N, et al. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab. 2003;88:993-7. (Pubitemid 36337745)
22. Wei EK, Giovannucci E, Fuchs CS, et al. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005;97:1688-94. (Pubitemid 41672235)
23. Dalamaga M, Karmaniolas K, Nikolaidou A, et al. Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system. Eur J Cancer. 2008;44:1744-53.
24. Ishikawa M, Kitayama J, Yamauchi T, et al. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci. 2007;98(7):1120-7. (Pubitemid 46865400)